Will Ascendis Pharma's stock price surpass $200 by December 31, 2024? | Binary | | | 3 months ago | |
Major pharmaceutical company to acquire Ascendis Pharma by end of 2024? | Categorical | | | 4 months ago | |
New hypoparathyroidism treatment announced by another company by end of 2024? | Binary | | | 4 months ago | |
Ascendis Pharma stock price increase by more than 20% by end of August 2024? | Binary | | | 4 months ago | |
Percentage increase in Ascendis Pharma's stock price by end of August 2024? | Categorical | | | 4 months ago | |
FDA warnings or recalls for YORVIPATH by end of 2024? | Binary | | | 4 months ago | |
YORVIPATH sales over $100 million by end of 2024? | Binary | | | 4 months ago | |
Ascendis Pharma stock increase by at least 20% by end of 2024? | Binary | | | 4 months ago | |
What will be the next major milestone for Ascendis Pharma's TransCon CNP by December 31, 2024? | Categorical | | | 3 months ago | |
Will Biomarin's Voxzogo lose more than 20% market share by June 30, 2025? | Binary | | | 3 months ago | |
How will Ascendis Pharma's stock react to the next update on TransCon CNP by March 31, 2025? | Categorical | | | 3 months ago | |
What will Ascendis Pharma's stock price be by December 31, 2024? | Categorical | | | 3 months ago | |
Will Ascendis Pharma's TransCon CNP receive FDA approval by December 31, 2024? | Binary | | | 3 months ago | |
Market share of YORVIPATH in US hypoparathyroidism treatment market by end of 2024? | Categorical | | | 4 months ago | |
Main competitor for Ascendis Pharma in hypoparathyroidism treatment by end of 2024? | Categorical | | | 4 months ago | |
FDA safety warning for Ascendis Pharma's YORVIPATH by end of 2024? | Binary | | | 4 months ago | |
Percentage increase in Ascendis Pharma's stock by end of 2024? | Categorical | | | 4 months ago | |
Company with highest market share in hypoparathyroidism treatments by end of 2024? | Categorical | | | 4 months ago | |
